Sandbox Reserved 1127
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
{{Sandbox_Reserved_ESBS_2015}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | {{Sandbox_Reserved_ESBS_2015}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | ||
==Human PDE5 structure and its inhibitor 5R== | ==Human PDE5 structure and its inhibitor 5R== | ||
| - | <StructureSection load='3jwq' size='340' side='right' caption=' | + | <StructureSection load='3jwq' size='340' side='right' caption='PDE5 and its inhibitor Sildenafil' scene=''> |
This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | ||
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue. | You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue. | ||
| Line 8: | Line 8: | ||
PDE5 is an phosphodiesterase : this enzyme catalyzes the hydrolysis of cGMP into 5'GMP. CGMP is an usual second messager in cell transduction. PDE5 regulates its concentration by hydrolysis. | PDE5 is an phosphodiesterase : this enzyme catalyzes the hydrolysis of cGMP into 5'GMP. CGMP is an usual second messager in cell transduction. PDE5 regulates its concentration by hydrolysis. | ||
Human PDE5 is a PDE of class I. | Human PDE5 is a PDE of class I. | ||
| + | PDE5 function affects the smooth muscle, blood vessels or penis, uterus and intestines. | ||
| - | == | + | == Medical application == |
If an inhibitor binds instead of cGMP, cGMP concentration increases and the stimulus continues. PDE5 inhibition is particulary used for erectile disfunction. | If an inhibitor binds instead of cGMP, cGMP concentration increases and the stimulus continues. PDE5 inhibition is particulary used for erectile disfunction. | ||
Sildenafil or VIagra is an inhibitor of PDE5. | Sildenafil or VIagra is an inhibitor of PDE5. | ||
| Line 16: | Line 17: | ||
== Structural highlights == | == Structural highlights == | ||
| - | PDE5 is a dimeric protein of about 270 amino acids long. The C terminal has the catalytic domain and two Zn2+ binding site and N temrinal is the regulatory domain which includes two the GAF domain a and b. There are thus plural allosteric binding site for cGMP in the Cterminal and the N terminal. cGAMP binds on Gap | + | PDE5 is a dimeric protein of about 270 amino acids long. The C terminal has the catalytic domain and two Zn2+ binding site and N temrinal is the regulatory domain which includes two the GAF domain a and b. There are thus plural allosteric binding site for cGMP in the Cterminal and the N terminal. cGAMP binds on Gap an allosteric site and promotes the phosphorylation of SER 92 of PKG. This phosphorylation increases the affinity between cGMP and PDE5. Another cGMP can bind to the Gap b which allows the activation of the catalytic site of PDE5. The activated catalytic site is now able to break the phosphodiesteric bond of cGMP :http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518390/) |
Revision as of 09:49, 28 January 2016
| This Sandbox is Reserved from 15/12/2015, through 15/06/2016 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1120 through Sandbox Reserved 1159. |
To get started:
More help: Help:Editing |
Human PDE5 structure and its inhibitor 5R
| |||||||||||
References
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
